In a landmark advancement for the treatment of advanced breast cancer, the U.S. Food and Drug Administration (FDA) has granted approval for the use of palbociclib in combination with trastuzumab, with or without pertuzumab, alongside endocrine therapy. This approval applies specifically to adult patients exhibiting hormone receptor–positive (HR+), human epidermal growth factor receptor 2–positive (HER2+) locally advanced or metastatic breast cancer who have undergone induction treatment. This new therapeutic indication not only marks a significant milestone in oncology drug development but also delivers renewed hope to a patient population often confronted with aggressive disease trajectories and limited treatment options.
The decision to approve palbociclib for this double-positive breast cancer subtype is grounded in robust clinical trial evidence, primarily from the phase III PATINA study, also known as Alliance Foundation Trials AFT-38. The trial’s findings demonstrated that incorporating the CDK4/6 inhibitor palbociclib into the standard first-line maintenance regimen significantly enhances progression-free survival (PFS). Specifically, patients treated with palbociclib experienced a 24% reduction in the risk of disease progression or death relative to those receiving standard therapy alone. These results underscore the therapeutic potential of targeting cell cycle pathways alongside established HER2-directed and endocrine therapies.
Dr. Evanthia Galanis, President of Alliance Foundation Trials and Chair of the Alliance for Clinical Trials in Oncology, highlighted the collaborative scientific endeavor underpinning this approval. Years of meticulous research and cooperation among international institutions culminated in the PATINA trial, which fundamentally reshaped clinical understanding of HR+/HER2+ advanced breast cancer management. The significant delay in disease progression observed affirms that palbociclib delivers a clinically relevant benefit, expanding the arsenal of treatments available to oncologists managing this challenging subset.
Approximately 10% of breast cancer cases globally are characterized by the concurrent positivity for hormone receptors and HER2 expression, referred to as double-positive or occasionally triple-positive breast cancer when progesterone receptor status is considered. These tumors, while historically responsive to anti-HER2 and endocrine therapies, often develop resistance mechanisms that compromise treatment efficacy. The intrinsic heterogeneity and complexity of this cancer subtype necessitate novel, strategic therapeutic interventions capable of overcoming or delaying resistance onset.
The PATINA trial was designed to address this unmet need by evaluating whether maintenance therapy that includes palbociclib could prolong disease control following initial induction chemotherapy combined with HER2-directed agents. Led by Dr. Otto Metzger of Dana-Farber Cancer Institute, the multicenter, randomized, open-label study rigorously assessed the efficacy and safety of this combination approach across a global patient cohort. The results illustrated not only a significant enhancement in median progression-free survival—from 29.1 months to an impressive 44.3 months—but also confirmed an acceptable safety profile with no emergent adverse effects, supporting its clinical viability.
This international study enrolled 518 patients from 109 medical centers spanning North America, Europe, Australia, and New Zealand. The rigorous trial design involved assigning patients who had completed induction treatment to receive either palbociclib in conjunction with anti-HER2 therapy and endocrine therapy or the standard dual therapy without palbociclib. The remarkable extension of progression-free survival observed with palbociclib integration represents a major breakthrough in the therapeutic landscape of HR+/HER2+ metastatic breast cancer, offering a new standard of care that may fundamentally alter disease trajectories.
The underlying mechanism driving the efficacy of palbociclib lies in its targeted inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6), crucial regulators of cell cycle progression. By arresting cancer cell proliferation at the G1 phase, palbociclib effectively complements HER2 blockade and hormone receptor antagonism. This multifaceted blockade hampers tumor growth more effectively than monotherapies or dual therapies, addressing the adaptive and resistant phenotypes frequently encountered in advanced breast cancer treatment.
The data supporting this FDA approval were previously published in the prestigious New England Journal of Medicine and presented at the 2024 San Antonio Breast Cancer Symposium, where the oncology community widely recognized the clinical significance of these findings. The high scientific rigor and the magnitude of clinical benefit reported in these forums underscored the trial’s impact and anticipated influence on practice guidelines worldwide.
The Alliance Foundation Trials’ Statistics and Data Center, led by Dr. Sumithra Mandrekar, played a pivotal role in managing and analyzing the voluminous and complex clinical data generated during PATINA. Their centralized clinical database and statistical monitoring ensured timely and accurate assessment of primary endpoints, facilitating rapid dissemination of critical trial outcomes that informed regulatory decisions. This exemplary data management highlights the importance of infrastructure in executing large-scale international oncology trials.
The PATINA study was funded by Pfizer Inc. and was the result of a broad academic partnership involving research organizations across multiple continents. Entities such as Breast Cancer Trials in Australia and New Zealand, Fondazione Michelangelo in Italy, GBG in Germany, PrECOG in the United States, SOLTI in Spain and Portugal, and Unicancer in France, collectively contributed to this global effort. This cooperative model not only enhanced patient accrual and diversity but also fostered a shared commitment to advancing breast cancer therapeutics.
With the FDA’s approval, clinicians now have at their disposal an evidence-based, regulatory-sanctioned option that integrates palbociclib into maintenance therapy post-induction, tailored specifically for HR+/HER2+ metastatic breast cancer. This advances personalized medicine paradigms and opens avenues for further clinical research aiming to optimize combination regimens, investigate resistance mechanisms, and improve long-term patient outcomes in this aggressive disease subset.
The emergence of palbociclib as a cornerstone in the management of double-positive breast cancer signifies a paradigm shift, validating the concept that simultaneous targeting of cell cycle regulators, hormone receptors, and HER2 pathways can yield substantial therapeutic synergy. This milestone in oncology not only redefines treatment algorithms but also galvanizes continued innovation towards overcoming treatment resistance—a pressing challenge in metastatic breast cancer therapeutics.
Subject of Research: Hormone receptor–positive (HR+), HER2-positive (HER2+) advanced breast cancer treatment
Article Title: FDA Approves Palbociclib Combination Therapy for HR+/HER2+ Advanced Breast Cancer Based on PATINA Trial Results
News Publication Date: June 24, 2026
Web References:
- New England Journal of Medicine: https://www.nejm.org/doi/full/10.1056/NEJMoa2511218
- San Antonio Breast Cancer Symposium, 2024 presentations
References:
PATINA (AFT-38) clinical trial data, Alliance Foundation Trials, LLC; Pfizer Oncology funding and support
Keywords: Palbociclib, HER2-positive breast cancer, hormone receptor-positive breast cancer, CDK4/6 inhibitor, FDA approval, progression-free survival, PATINA trial, targeted therapy, metastatic breast cancer, combination therapy
